

RESEARCH ARTICLE

# A Second Look at the Association between Gender and Mortality on Antiretroviral Therapy

Serena P. Koenig<sup>1,2\*</sup>, Alexandra Bornstein<sup>3</sup>, Karine Severe<sup>1</sup>, Elizabeth Fox<sup>4</sup>, Jessy G. Dévieux<sup>5</sup>, Patrice Severe<sup>1</sup>, Patrice Joseph<sup>1</sup>, Adias Marcelin<sup>1</sup>, Dgndy Alexandre Bright<sup>1</sup>, Ngoc Pham<sup>3</sup>, Pierre Cremieux<sup>3</sup>, Jean William Pape<sup>1,6</sup>

**1** Haitian Study Group for Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti, **2** Division of Global Health Equity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States of America, **3** Analysis Group, Boston, MA, United States of America, **4** Division of Nutritional Sciences, Cornell University, Ithaca, NY, United States of America, **5** AIDS Prevention Program, Florida International University, Miami, FL, United States of America, **6** Center for Global Health, Weill Cornell Medical College, New York, NY, United States of America

\* [skoenig@partners.org](mailto:skoenig@partners.org)



**OPEN ACCESS**

**Citation:** Koenig SP, Bornstein A, Severe K, Fox E, Dévieux JG, Severe P, et al. (2015) A Second Look at the Association between Gender and Mortality on Antiretroviral Therapy. PLoS ONE 10(11): e0142101. doi:10.1371/journal.pone.0142101

**Editor:** Dimitrios Paraskevis, University of Athens, Medical School, GREECE

**Received:** May 27, 2015

**Accepted:** October 16, 2015

**Published:** November 12, 2015

**Copyright:** © 2015 Koenig et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information file.

**Funding:** The project was supported in part by the National Institute of Allergy and Infectious Diseases (NIAID) Grant Number R01AI104344 and the Fogarty International Center Grant Number D43TW009606. No funder was involved in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

## Abstract

### Objective

We assessed the association between gender and mortality on antiretroviral therapy (ART) using identical models with and without sex-specific categories for weight and hemoglobin.

### Design

Cohort study of adult patients on ART.

### Setting

GHESKIO Clinic in Port-au-Prince, Haiti.

### Participants

4,717 ART-naïve adult patients consecutively enrolled on ART at GHESKIO from 2003 to 2008.

### Main Outcome Measure

Mortality on ART; multivariable analyses were conducted with and without sex-specific categories for weight and hemoglobin.

### Results

In Haiti, male gender was associated with mortality (OR 1.61; 95% CI: 1.30–2.00) in multivariable analyses with hemoglobin and weight included as control variables, but not when sex-specific interactions with hemoglobin and weight were used.

## Conclusions

If sex-specific categories are omitted, multivariable analyses indicate a higher risk of mortality for males vs. females of the same weight and hemoglobin. However, because males have higher normal values for weight and hemoglobin, the males in this comparison would generally have poorer health status than the females. This may explain why gender differences in mortality are sometimes observed after controlling for differences in baseline variables when gender-specific interactions with weight and hemoglobin are omitted.

## Introduction

Nearly 10 million people were receiving antiretroviral therapy (ART) in low and middle-income countries by the end of 2012, an estimated 61% of patients who were eligible under the 2010 World Health Organization (WHO) guidelines [1]. Though ART scale-up is widely viewed as highly successful, questions have been raised about gender equity in access to services [2–5]. Women have been prioritized by funding agencies, international organizations, and local governments, with a focus on the prevention of mother-to-child transmission of HIV [6]. These efforts have resulted in proportionally greater numbers of women receiving HIV testing and ART [7].

Male gender is associated with late HIV testing and more advanced disease at ART initiation [8–18], which is strongly associated with poorer outcomes [19]. Even after controlling for differences in disease severity and other baseline characteristics, multiple studies have found that males have higher mortality after ART initiation [8, 10–13, 20–33]. Proposed reasons for this mortality difference include inequality for males in health care systems in low and middle-income countries, poorer treatment adherence, irregular clinic attendance due to work-related responsibilities, a higher baseline mortality rate for males in the general population, potentially biological differences, and other unmeasured confounders or uncharacterized mechanisms that lead to poorer outcomes for males [2, 3, 5, 8, 12, 34–37].

In Haiti, we found differing results in two studies on predictors of mortality after ART initiation. The earlier study included gender-specific weight quartiles, and did not find an association between male gender and mortality (hemoglobin was not included in the analyses) [38]. The later study included weight and hemoglobin as continuous variables, and found that male gender was associated with higher mortality [39]. We reviewed the literature, and found that many other ART outcomes studies also included weight and hemoglobin without sex-specific categories [8–12, 20–23, 30, 31, 33]. These analyses compare mortality among males vs. females with the same weight and hemoglobin. Due to normal sex differences in these variables, this is not a comparison of males and females of equivalent health status. We therefore repeated the analyses for our later study, adding sex-specific categories for weight and hemoglobin.

## Methods

### Study Setting and Participants

The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections is a Haitian non-governmental organization, and the oldest and largest provider of HIV services in the Caribbean. GHESKIO has provided voluntary counseling and testing (VCT) for HIV since 1985. This study included all ART-naïve HIV-infected patients 13 years or older who were

consecutively enrolled on ART from February 1, 2003 (when ART became widely available at GHESKIO) to December 31, 2008. Patients were followed until December 31, 2009.

## Data Collection and Statistical Analyses

Data were extracted from the GHESKIO electronic medical record and entered into a Microsoft Access database (Microsoft, Redmond, WA). Baseline weight, hemoglobin, and CD4 cell count were defined as the measurement closest to the date of ART initiation, but not more than six months before or two weeks afterwards. Death was ascertained by chart review, phone calls to next of kin, and home visits. Patients were considered to be alive and in-care if they were not known to be dead and had at least one visit within 6 months of the study endpoint. All analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC). Patients who were lost to care or transferred to other clinics were censored at their last visit.

Differences between males and females in age, education, income, TB status at ART initiation, initial ART regimen (drug class), and baseline weight, hemoglobin and CD4 cell count were compared using the Chi-square test for binary variables and Wilcoxon rank-sum test for continuous variables. Cox proportional hazards models were used to assess the relationship between baseline demographic and clinical variables and time to death after ART initiation. Gender, income, education, initial ART regimen, and active TB co-infection at ART initiation were defined as binary variables; and hemoglobin, weight, age and CD4 cell count were defined as continuous variables. In the multivariable models we included all variables significant at the 0.20 level in univariable analyses.

We included weight and hemoglobin in the analyses of all-cause mortality using five different models. In Model 1, we included baseline weight and hemoglobin as control variables, without specifying these variables differently for males and females; the interpretation of this model is the risk of mortality for males vs. females who presented with the same baseline weight and hemoglobin. In Model 2, we included weight and hemoglobin using differences from the sex-specific median; the interpretation of this model is the risk of mortality for males vs. females who have the same deviation from the sex-specific cohort medians for these variables. The goal of Model 3 was to compare mortality for males vs. females with the same deviation from a healthy sex-specific standard for weight and hemoglobin. Since there is no standard measure of healthy weight without the inclusion of height, and height was not measured, we used deviation from gender-specific median for weight. For hemoglobin, we used the WHO definition of anemia as a binary variable (cut-off of 12 g/dL for women and 13 g/dL for men) [40]. In Model 4, we used sex-specific quartiles for weight and hemoglobin; the interpretation of this model is the risk of mortality for males vs. females who fall within the same sex-specific cohort quartiles for these variables. In Model 5, we excluded any weight or hemoglobin-related variables but included all other variables as in the other models. Our rationale for the inclusion of Model 5 is for comparability with other studies that did not include these variables. We included an anonymized dataset (see [S1 Appendix](#)) that includes all data needed to reproduce these results.

## Ethics Statement

This study was approved by the ethics committees of GHESKIO, Weill Cornell Medical College, and Brigham and Women's Hospital. It was not feasible to obtain informed consent for this retrospective study, but patient information was anonymized and de-identified prior to analysis.

## Results

The 4,717 ART-naïve HIV-infected patients age 13 years or older who were consecutively enrolled on ART during the study period were included. Characteristics for males and females

are summarized in [Table 1](#). The cohort included 2,151 males (46%) and 2,566 females (54%). Males were older (median age 40 vs. 36 years;  $p < 0.0001$ ), less likely to live on  $\leq$ US\$365/year (53% vs. 71%;  $p < 0.0001$ ), less likely to have no school or primary school only (43% vs. 56%;  $p < 0.0001$ ), and more likely to have TB at ART initiation (6% vs. 4%;  $p < 0.0001$ ). At baseline, males had higher median body weight (57 vs. 50 kilograms;  $p < 0.0001$ ), higher median hemoglobin (11.0 vs. 10.0 g/dl;  $p < 0.0001$ ), and lower median CD4 counts (134 vs. 105 cells/mm<sup>3</sup>). The median follow-up time was 828 days (interquartile range (IQR): 388 to 1,505 days) for males and 825 days (IQR: 395 to 1,492 days) for females. Of the 4717 patients in the cohort, 293 males (14%) and 305 females (12%) died during the study period; 602 patients (13%) were lost to follow-up, including 288 males (13%) and 314 females (12%). The LTFU rates were not statistically significantly different between sexes ( $p = 0.2375$ ).

### Univariable and Multivariable Analyses without Sex-Specific Categories for Weight and Hemoglobin

We conducted Cox proportional hazards regression with baseline weight and hemoglobin as non-sex specific variables. In the univariable analysis, gender, age, income, weight, hemoglobin, CD4 cell count, and TB status at ART initiation had  $p$ -values  $< 0.20$ , and were included in the multivariable analyses. Education and ART regimen were not associated with mortality ( $p = 0.503$  and  $0.674$ , respectively) and were excluded from further analyses.

The sample size for the multivariable analysis was 3761 patients. Nine hundred fifty-six patients were missing at least one of the independent variables. Male gender (adjusted hazard ratio [aHR] 1.61; 95% CI: 1.30–2.00) and older age were associated with mortality (aHR 1.22 for every 10-year increase in age; 95% CI: 1.11–1.34). Higher baseline weight (aHR 0.63 for every 10-kilogram increase in weight; 95% CI: 0.56–0.70), hemoglobin (aHR 0.87; 95% CI: 0.82–0.92), and CD4 cell count (aHR 0.87 for every 50 CD4 cells; 95% CI: 0.82–0.93) were associated with improved survival (see [Table 2](#), Model 1).

### Multivariable Analyses Using Sex-Specific Categories for Weight and Hemoglobin

We conducted three different additional analyses using sex-specific categories for weight and hemoglobin, as described above (Models 2, 3, and 4). As illustrated in [Tables 2](#) and [3](#), in each of these three models, older age was associated with mortality. Higher baseline weight, hemoglobin, and CD4 cell count were associated with improved survival. Male gender was not a predictor of mortality.

We repeated the analyses with the exclusion of any baseline hemoglobin or weight control variables, for comparison with studies that did not include these variables in the analyses (see [Table 4](#), Model 5). With the exclusion of these variables, male gender was not associated with higher mortality. Older age and income  $\leq$ US 365 per year were associated with higher mortality, and higher CD4 cell count was associated with improved survival.

## Discussion

In Haiti, as in most other resource-poor settings, male gender is associated with advanced disease at ART initiation [8–18]. However, we found that after controlling for baseline differences, the association between male gender and mortality on ART depended on whether or not sex-specific categories were used for weight and hemoglobin. Without the use of sex-specific categories, we found that the adjusted hazard ratio of mortality for males was 1.61 (1.30–2.00).

**Table 1. Baseline Patient Characteristics by Gender.**

Variable*	Male (n = 2,151)	Female (n = 2,566)	P-value
Median Age (IQR)**	40 (33 to 46)	36 (33 to 43)	<0.0001
No school or primary school only—no. (%)	931 (43)	1,435 (56)	<0.0001
Income ≤US\$365/year—no. (%)	1,148 (53)	1,813 (71)	<0.0001
Median weight—kilograms (IQR)**	57 (50–64)	50 (44–58)	<0.0001
Median hemoglobin—g/dl (IQR)**	11.0 (9.6–12.2)	10.0 (8.9–11.0)	<0.0001
Hemoglobin <8.0 (g/dl)—no. (%)	116 (5)	234 (9)	<0.0001
Hemoglobin 8.0–10.9 (g/dl)—no. (%)	835 (39)	1,422 (55)	
Hemoglobin 11.0–12.9 (g/dl)—no. (%)	694 (32)	585 (23)	
Hemoglobin ≥13.0	287 (13)	46 (2)	
Median CD4 cell count (IQR)**	105 (39–182)	134 (59–198)	<0.0001
CD4 cell count <50 cells/mm <sup>3</sup>	561 (29)	513 (22)	<0.0001
CD4 cell count 50–99 cells/mm <sup>3</sup>	372 (19)	404 (17)	
CD4 cell count 100–199 cells/mm <sup>3</sup>	648 (33)	853 (36)	
CD4 cell count ≥ 200 cells/mm <sup>3</sup>	370 (19)	573 (24)	
TB at ART initiation—no. (%)	126 (6)	107 (4)	0.0077
ART regimen includes non-nucleoside reverse transcriptase inhibitor	2,044 (95)	2,431 (95)	0.6567

\* Two variables had ≥5% of data missing. There were 219 (10%) missing hemoglobin results for males and 279 (11%) for females. There were 200 (9%) missing CD4 count results for males and 223 (9%) for females.

\*\*Median values and percentages are computed using the number of patients with non-missing values.

doi:10.1371/journal.pone.0142101.t001

Male gender was not associated with mortality if sex-specific categories were used for weight and hemoglobin, or these variables were excluded from the analysis.

Many studies from resource-poor settings have described higher rates of mortality for males on ART [8–13, 17, 20–33, 41, 42]. However, these studies did not use sex-specific categories for both weight and hemoglobin, and therefore indicate a higher mortality for males vs. females of the same weight and hemoglobin. As the males in this comparison would generally have poorer health status at equal baseline weight and hemoglobin levels, higher mortality would be expected.

**Table 2. Cox Proportional Hazards Models of Mortality on ART using Different Methods of Categorizing Weight and Hemoglobin (Models 1, 2, and 3).**

Variable	Model 1: Weight and hemoglobin as continuous variables		Model 2: Deviation from gender-specific median for weight and hemoglobin		Model 3: Deviation from gender-specific median weight and gender-specific WHO anemia definition*	
	Adjusted HR (95% CI)	p-value	Adjusted HR (95% CI)	p-value	Adjusted HR (95% CI)	p-value
Male gender	1.61 (1.30–2.00)	<0.0001	1.05 (0.85–1.29)	0.6437	1.04 (0.84–1.27)	0.7444
Age (unit = 10 years)	1.22 (1.11–1.34)	<0.0001	1.22 (1.11–1.34)	<0.0001	1.22 (1.11–1.34)	<0.0001
Income ≤US\$365 per year	1.22 (0.97–1.54)	0.0884	1.22 (0.97–1.54)	0.0884	1.22 (0.97–1.54)	0.0884
Weight (unit = 10 kilograms)	0.63 (0.56–0.70)	<0.0001	0.63 (0.56–0.70)	<0.0001	0.63 (0.56–0.70)	<0.0001
Hemoglobin (g/dl)	0.87 (0.82–0.92)	<0.0001	0.87 (0.82–0.92)	<0.0001	0.87 (0.82–0.92)	<0.0001
CD4 cell count (unit = 50 cells)	0.87 (0.82–0.93)	<0.0001	0.87 (0.82–0.93)	<0.0001	0.87 (0.82–0.93)	<0.0001
TB at ART initiation	1.39 (0.97–1.98)	0.0711	1.39 (0.97–1.99)	0.0711	1.39 (0.97–1.99)	0.0711

\*Difference from gender-specific median for weight, and World Health Organization definition of anemia (≤12.0 g/dl for women and ≤13.0 g/dl for men)

doi:10.1371/journal.pone.0142101.t002

**Table 3. Cox Proportional Hazards Model of Mortality on ART Using Gender-Specific Quartiles for Hemoglobin and Weight (Model 4).**

Variable	Model 4: Adjusted HR (95% CI)	p-value
Male gender	1.12 (0.91–1.38)	0.2813
Age (unit = 10 years)	1.18 (1.08–1.30)	<0.0001
Income ≤\$US365/year	1.30 (1.03–1.63)	0.0269
Weight—reference group bottom quartile		
— Quartile 2 for gender	0.49 (0.37–0.64)	<0.0001
— Quartile 3 for gender	0.41 (0.31–0.54)	<0.0001
— Quartile 4 for gender	0.39 (0.28–0.54)	<0.0001
Hemoglobin—reference group bottom quartile		
— Quartile 2 for gender	0.58 (0.44–0.75)	<0.0001
— Quartile 3 for gender	0.66 (0.50–0.87)	0.0029
— Quartile 4 for gender	0.47 (0.34–0.66)	<0.0001
CD4 cell count (unit = 50 cells)	0.87 (0.82–0.92)	<0.0001
TB at ART initiation	1.36 (0.95–1.95)	0.0910

doi:10.1371/journal.pone.0142101.t003

Six of these studies from China, South Africa, and Tanzania included body weight in the analyses without sex-specific categories [8, 10, 11, 22, 29, 33]. Though BMI is a superior predictor of nutritional status as it includes height, it is not always available, and weight is used as a proxy. All six of these studies found that male gender was associated with higher mortality. Studies from Cambodia, Thailand, Burkina Faso, Cameroon, Cote d’Ivoire, Malawi, Nigeria and Tanzania used body mass index, and none of these used sex-specific categories [9, 12, 20, 21, 23, 27, 28, 30, 31]. BMI is commonly used as a predictor of disease in high BMI ranges without sex-specific categories. However, there is limited evidence linking low BMI ranges to disease outcomes in the developing country context, particularly when sex-specific categories are not used [43–45]. In addition, BMI poorly discriminates between body composition phenotypes, i.e. bone mass, fat mass and lean muscle mass [43, 46], and significant sex differences exist in body composition phenotypes [43, 47, 48]. Thus, the same BMI value may have different implications for the health and nutritional status of HIV-infected men and women.

Most studies from resource-poor settings that included hemoglobin did not include sex-specific categories [9, 11, 12, 20–23, 30, 31]. However, criteria for anemia are sex-specific. WHO defines anemia as a hemoglobin level below 12 g/dL in females and below 13 g/dL in males [40], and multiple studies evaluating outcomes in other diseases have used sex-specific categories for hemoglobin [49–53]. Most studies that did not use sex-specific hemoglobin categories found an association between male gender and mortality [11, 12, 20–23, 30, 31]. One study from Cambodia did not use sex-specific hemoglobin categories and found no association

**Table 4. Cox Proportional Hazards Models of Mortality on ART with the Exclusion of Weight and Hemoglobin (Model 5).**

Variable	Model 5: No interaction	
	Adjusted HR (95% CI)	p-value
Male gender	1.15 (0.93–1.41)	0.2003
Age (unit = 10 years)	1.16 (1.05–1.28)	0.0037
Income ≤\$US365 per year	1.53 (1.22–1.92)	0.0002
CD4 cell count (unit = 50 cells)	0.83 (0.78–0.88)	<0.0001
TB at ART initiation	1.61 (1.13–3.00)	0.0886

doi:10.1371/journal.pone.0142101.t004



between gender and mortality, but it included patients who were severely immunocompromised (median CD4 cell count of 20 cells/mm<sup>3</sup>), making comparisons with other cohorts difficult [9]. One South African study included sex-specific categories for hemoglobin, and found an association between male gender and mortality [8]. However, this study included weight as a continuous variable, without sex-specific categories. The authors also compared the gender differential in mortality among patients on ART to the background gender differential in mortality in the South African population. They found that the gender mortality ratio among patients on ART appeared to be smaller than the age-standardized HIV-negative mortality ratio for men vs. women in South Africa, suggesting that higher background mortality rates among males contributed to the association with mortality on ART. Therefore, the finding of the association between male gender and mortality on ART could be misinterpreted.

Several studies from India, Ethiopia, Lesotho, Malawi, South Africa, and Uganda did not include either weight or hemoglobin in the analyses [13, 17, 24–26, 32, 41, 42]. These studies generally involved retrospective cohorts, and data for these variables had not been collected. Hemoglobin and weight provide two additional metrics to proxy the underlying baseline health status of patients, when they are available. Models that exclude hemoglobin and weight should result in a weaker relationship between gender and mortality than models that include these variables without attention to sex-specific differences in healthy values. However, because these studies do not explicitly control for sex-specific differences in healthy weight and hemoglobin levels, they are still likely to overstate male mortality. Some studies that had not included these variables found an association between male gender and mortality on ART [13, 24–26, 32] while others did not [17, 41, 42].

Though our study found that male gender was not associated with higher mortality after controlling for baseline characteristics that proxy for disease severity with attention to sex-specific differences in healthy weight and hemoglobin, this does not diminish concern about equity in access to care for males [2–5, 13, 27, 28]. In our analysis as in others, males present later for HIV testing, and start ART with more advanced disease; such delays in ART initiation are associated with higher morbidity and poorer long-term survival [19]. Innovative outreach efforts for earlier HIV testing and timely ART initiation for males remain critical to maximize HIV treatment outcomes, particularly since our analysis shows that, controlling for baseline characteristics that proxy for disease severity, there is no evidence of lower survival for males relative to females after ART initiation.

Our study was limited by the use of retrospective data from a single country, and by our lack of BMI data. It was also limited by the lack of information about mortality in patients who were LTFU. We did not correct mortality for LTFU in our analyses. Our rate of LTFU (13% with median follow-up time of 27 months) is lower than in many studies from resource-poor settings [54, 55], and was similar in males and females. We wanted to compare our findings to other published studies evaluating the sex differences in ART outcomes. These studies either did not correct mortality for LTFU [10, 11, 20, 22, 27, 28, 30], conducted separate analyses to identify predictors of mortality and LTFU [12, 17, 23–25, 31, 32, 42], or used weighted data or competing risk models (either in the base case analysis or in sensitivity analyses) to correct mortality estimates for those who were LTFU but had died [8, 9, 13, 21, 26, 29, 33, 41].

In comparing our study with others from resource-poor settings that evaluated the association between gender and mortality on ART, it is important to also consider that normal weight and hemoglobin values vary by age and ethnicity. All patients in our cohort were Haitian, of African descent. The median age in our study was 38 years, and we included patients of at least 13 years of age. The median age in other studies ranged from 32 to 39 years [8–13, 17, 20–33, 41, 42], and many included adolescents as well as adult patients [8, 12, 13, 20, 21, 24–28, 32, 33].

The association between gender and ART outcomes is complex, and the reasons for gender differences vary by settings. However, our finding that the association between gender and mortality is no longer observed once sex-specific baseline characteristics are included has relevance for other countries and other diseases.

In summary, we found that males do not have higher mortality after ART initiation, as long as sex-specific categories for weight and hemoglobin are included to allow a comparison of gender-specific survival given similar morbidity levels at baseline. If sex-specific categories are not used, then the hazard ratio must be interpreted as a comparison of males and females with the same weight and hemoglobin but not the same baseline morbidity levels.

## Supporting Information

**S1 Appendix. Anonymized Dataset.**  
(XLS)

## Acknowledgments

We would like to acknowledge Sidney Atwood for his assistance and advice in conducting the analyses.

## Author Contributions

Conceived and designed the experiments: SPK AB KS EF JGD PS PJ AM DAB NP PC JWP. Analyzed the data: SPK AB KS EF JGD PS PJ AM DAB NP PC JWP. Wrote the paper: SPK AB KS EF JGD PS PJ AM DAB NP PC JWP. Provided clinical care for the patients: KS PS PJ JWP.

## References

1. Global Report. UNAIDS Report on the Global AIDS Epidemic 2013. Available: [http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS\\_Global\\_Report\\_2013\\_en.pdf](http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf). Accessed 1 November 2014.
2. Druyts E, Dybul M, Kanters S, Nachega J, Birungi J, Ford N, et al. Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. *AIDS* 2013, 27:417–425. PMID: [22948271](https://pubmed.ncbi.nlm.nih.gov/22948271/)
3. Cornell M, Myer L. Does the success of HIV treatment depend on gender? *Future Microbiol* 2013, 8:9–11. doi: [10.2217/fmb.12.128](https://doi.org/10.2217/fmb.12.128) PMID: [23252488](https://pubmed.ncbi.nlm.nih.gov/23252488/)
4. Cornell M. Gender inequality: Bad for men's health. *South Afr J HIV Med* 2013, 14:12–14. PMID: [24078805](https://pubmed.ncbi.nlm.nih.gov/24078805/)
5. Johannessen A. Are men the losers of the antiretroviral treatment scale-up? *AIDS* 2011, 25:1225–1226. PMID: [21593620](https://pubmed.ncbi.nlm.nih.gov/21593620/)
6. The United State's President's Emergency Response to AIDS Relief. A Woman and Girl-Centered Approach to Health and Gender Equity. Available: <http://www.pepfar.gov/about/strategy/ghi/134852.htm>. Accessed 11 June 2014.
7. Braitstein P, Boulle A, Nash D, Brinkhof MW, Dabis F, Laurent C, et al. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. *J Womens Health (Larchmt)* 2008, 17:47–55.
8. Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. *PLoS Med* 2012, 9:e1001304. PMID: [22973181](https://pubmed.ncbi.nlm.nih.gov/22973181/)
9. Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, Ngeth C, et al. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. *AIDS* 2007, 21:351–359. PMID: [17255742](https://pubmed.ncbi.nlm.nih.gov/17255742/)
10. MacPherson P, Moshabela M, Martinson N, Pronyk P. Mortality and loss to follow-up among HAART initiators in rural South Africa. *Trans R Soc Trop Med Hyg* 2009, 103:588–593. doi: [10.1016/j.trstmh.2008.10.001](https://doi.org/10.1016/j.trstmh.2008.10.001) PMID: [19012940](https://pubmed.ncbi.nlm.nih.gov/19012940/)



11. Mutevedzi PC, Lessells RJ, Heller T, Barnighausen T, Cooke GS, Newell ML. Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: does rapid expansion affect patient outcomes? *Bull World Health Organ* 2010, 88:593–600. doi: [10.2471/BLT.09.069419](https://doi.org/10.2471/BLT.09.069419) PMID: [20680124](https://pubmed.ncbi.nlm.nih.gov/20680124/)
12. Hawkins C, Chalamilla G, Okuma J, Spiegelman D, Hertzmark E, Aris E, et al. Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting. *AIDS* 2011, 25:1189–1197. PMID: [21505309](https://pubmed.ncbi.nlm.nih.gov/21505309/)
13. Mills EJ, Bakanda C, Birungi J, Chan K, Hogg RS, Ford N, et al. Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda. *J Int AIDS Soc* 2011, 14:52. doi: [10.1186/1758-2652-14-52](https://doi.org/10.1186/1758-2652-14-52) PMID: [22050673](https://pubmed.ncbi.nlm.nih.gov/22050673/)
14. Kumarasamy N, Venkatesh KK, Cecelia AJ, Devaleenol B, Saghayam S, Yepthomi T, et al. Gender-based differences in treatment and outcome among HIV patients in South India. *J Womens Health (Larchmt)* 2008, 17:1471–1475.
15. Auld AF, Mbofana F, Shiraishi RW, Sanchez M, Alfredo C, Nelson LJ, et al. Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. *PLoS One* 2011, 6:e18453. doi: [10.1371/journal.pone.0018453](https://doi.org/10.1371/journal.pone.0018453) PMID: [21483703](https://pubmed.ncbi.nlm.nih.gov/21483703/)
16. Alibhai A, Kipp W, Saunders LD, Senthilselvan A, Kaler A, Houston S, et al. Gender-related mortality for HIV-infected patients on highly active antiretroviral therapy (HAART) in rural Uganda. *Int J Womens Health* 2010, 2:45–52. PMID: [21072296](https://pubmed.ncbi.nlm.nih.gov/21072296/)
17. Cornell M, Myer L, Kaplan R, Bekker LG, Wood R. The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. *Trop Med Int Health* 2009, 14:722–731. doi: [10.1111/j.1365-3156.2009.02290.x](https://doi.org/10.1111/j.1365-3156.2009.02290.x) PMID: [19413745](https://pubmed.ncbi.nlm.nih.gov/19413745/)
18. Kipp W, Alibhai A, Saunders LD, Senthilselvan A, Kaler A, Konde-Lule J, et al. Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda. *AIDS Care* 2010, 22:271–278. doi: [10.1080/09540120903193625](https://doi.org/10.1080/09540120903193625) PMID: [20390506](https://pubmed.ncbi.nlm.nih.gov/20390506/)
19. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. *N Engl J Med* 2010, 363:257–265. doi: [10.1056/NEJMoa0910370](https://doi.org/10.1056/NEJMoa0910370) PMID: [20647201](https://pubmed.ncbi.nlm.nih.gov/20647201/)
20. Kouanda S, Meda IB, Nikiema L, Tiendrebeogo S, Doulogou B, Kabore I, et al. Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study. *AIDS Care* 2012, 24:478–490. doi: [10.1080/09540121.2011.630353](https://doi.org/10.1080/09540121.2011.630353) PMID: [22148973](https://pubmed.ncbi.nlm.nih.gov/22148973/)
21. Sieleunou I, Souleymanou M, Schonenberger AM, Menten J, Boelaert M. Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon. *Trop Med Int Health* 2009, 14:36–43.
22. Zhang F, Dou Z, Ma Y, Zhao Y, Liu Z, Bulterys M, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. *Ann Intern Med* 2009, 151:241–251, W-252. PMID: [19687491](https://pubmed.ncbi.nlm.nih.gov/19687491/)
23. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. *AIDS* 2008, 22:873–882. PMID: [18427206](https://pubmed.ncbi.nlm.nih.gov/18427206/)
24. Mulissa Z, Jerene D, Lindtjorn B. Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. *PLoS One* 2010, 5:e13268. doi: [10.1371/journal.pone.0013268](https://doi.org/10.1371/journal.pone.0013268) PMID: [20949010](https://pubmed.ncbi.nlm.nih.gov/20949010/)
25. Alvarez-Uria G, Naik PK, Pakam R, Midde M. Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: data from an HIV cohort study in India. *Glob Health Action* 2013, 6:21682. doi: [10.3402/gha.v6i0.21682](https://doi.org/10.3402/gha.v6i0.21682) PMID: [24028937](https://pubmed.ncbi.nlm.nih.gov/24028937/)
26. Weigel R, Estill J, Egger M, Harries AD, Makombe S, Tweya H, et al. Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. *AIDS* 2012, 26:365–373. PMID: [22095194](https://pubmed.ncbi.nlm.nih.gov/22095194/)
27. Chen SC, Yu JK, Harries AD, Bong CN, Kolola-Dzimadzi R, Tok TS, et al. Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. *Trop Med Int Health* 2008, 13:513–519. doi: [10.1111/j.1365-3156.2008.02029.x](https://doi.org/10.1111/j.1365-3156.2008.02029.x) PMID: [18282238](https://pubmed.ncbi.nlm.nih.gov/18282238/)
28. DeSilva MB, Merry SP, Fischer PR, Rohrer JE, Isichei CO, Cha SS. Youth, unemployment, and male gender predict mortality in AIDS patients started on HAART in Nigeria. *AIDS Care* 2009, 21:70–77. doi: [10.1080/09540120802017636](https://doi.org/10.1080/09540120802017636) PMID: [19085222](https://pubmed.ncbi.nlm.nih.gov/19085222/)
29. Boule A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, Mathee S, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. *AIDS* 2010, 24:563–572. PMID: [20057311](https://pubmed.ncbi.nlm.nih.gov/20057311/)

30. Fregonese F, Collins IJ, Jourdain G, Lecoer S, Cressey TR, Ngo-Giang-Huong N, et al. Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand. *J Acquir Immune Defic Syndr* 2012, 60:91–98. PMID: [22293548](#)
31. Maskew M, Brennan AT, MacPhail AP, Sanne IM, Fox MP. Poorer ART outcomes with increasing age at a large public sector HIV clinic in Johannesburg, South Africa. *J Int Assoc Physicians AIDS Care (Chic)* 2012, 11:57–65.
32. Nglazi MD, Lawn SD, Kaplan R, Kranzer K, Orrell C, Wood R, et al. Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. *J Acquir Immune Defic Syndr* 2011, 56:e1–8. PMID: [21084996](#)
33. Somi G, Keogh SC, Todd J, Kilama B, Wringe A, van den Hombergh J, et al. Low mortality risk but high loss to follow-up among patients in the Tanzanian national HIV care and treatment programme. *Trop Med Int Health* 2012, 17:497–506. doi: [10.1111/j.1365-3156.2011.02952.x](#) PMID: [22296265](#)
34. Leichter JS, Paz-Bailey G, Friedman AL, Habel MA, Vezi A, Sello M, et al. 'Clinics aren't meant for men': sexual health care access and seeking behaviours among men in Gauteng province, South Africa. *SAHARA J* 2011, 8:82–88. doi: [10.1080/17290376.2011.9724989](#) PMID: [23237685](#)
35. Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. *Am J Epidemiol* 2008, 168:532–540. doi: [10.1093/aje/kwn179](#) PMID: [18663213](#)
36. Perez-Elias MJ, Muriel A, Moreno A, Martinez-Colubi M, Iribarren JA, Masia M, et al. Relevant gender differences in epidemiological profile, exposure to first antiretroviral regimen and survival in the Spanish AIDS Research Network Cohort. *Antivir Ther* 2014, 19:375–385. doi: [10.3851/IMP2714](#) PMID: [24304821](#)
37. Antiretroviral Therapy Cohort, Collaboration. Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US. *Antivir Ther* 2015, 20:21–28. doi: [10.3851/IMP2768](#) PMID: [24675571](#)
38. Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. *N Engl J Med* 2005, 353:2325–2334. PMID: [16319381](#)
39. Koenig SP, Rodriguez LA, Bartholomew C, Edwards A, Carmichael TE, Barrow G, et al. Long-term antiretroviral treatment outcomes in seven countries in the Caribbean. *J Acquir Immune Defic Syndr* 2012, 59:e60–71. PMID: [22240464](#)
40. Hemoglobin concentrations for the diagnosis of anemia and assessment of severity. Geneva, Switzerland, World Health Organization, 2011. Available: <http://www.who.int/vmnis/indicators/haemoglobin.pdf>. Accessed 23 April 2013.
41. Ford N, Kranzer K, Hilderbrand K, Jouquet G, Goemaere E, Vlahakis N, et al. Early initiation of antiretroviral therapy and associated reduction in mortality, morbidity and defaulting in a nurse-managed, community cohort in Lesotho. *AIDS* 2010, 24:2645–2650. PMID: [20980868](#)
42. Boyles TH, Wilkinson LS, Leisegang R, Maartens G. Factors influencing retention in care after starting antiretroviral therapy in a rural South African programme. *PLoS One* 2011, 6:e19201. doi: [10.1371/journal.pone.0019201](#) PMID: [21559280](#)
43. WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. *World Health Organ Tech Rep Ser.* 1995; 854:1–452.
44. Garcia M, Kennedy E. Assessing the linkages between low body mass index and morbidity in adults: evidence from four developing countries. *Eur J Clin Nutr* 1994, 48 Suppl 3:S90–96; discussion S97. PMID: [7843164](#)
45. Khongsdier R. Body mass index and morbidity in adult males of the War Khasi in Northeast India. *Eur J Clin Nutr* 2002, 56:484–489. PMID: [12032646](#)
46. Prado CM, Siervo M, Mire E, Heymsfield SB, Stephan BC, Broyles S, et al. A population-based approach to define body-composition phenotypes. *Am J Clin Nutr* 2014, 99:1369–1377. doi: [10.3945/ajcn.113.078576](#) PMID: [24760978](#)
47. Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heymsfield SB. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? *Am J Epidemiol* 1996, 143:228–239. PMID: [8561156](#)
48. Nieves JW, Formica C, Ruffing J, Zion M, Garrett P, Lindsay R, et al. Males have larger skeletal size and bone mass than females, despite comparable body size. *J Bone Miner Res* 2005, 20:529–535. PMID: [15746999](#)
49. Thaler-Kall K, Doring A, Peters A, Thorand B, Grill E, Koenig W, et al. Association between anemia and falls in community-dwelling older people: cross-sectional results from the KORA-Age study. *BMC Geriatr* 2014, 14:29. doi: [10.1186/1471-2318-14-29](#) PMID: [24602338](#)

50. Martinsson A, Andersson C, Andell P, Koul S, Engstrom G, Smith JG. Anemia in the general population: prevalence, clinical correlates and prognostic impact. *Eur J Epidemiol* 2014, 29:489–498. doi: [10.1007/s10654-014-9929-9](https://doi.org/10.1007/s10654-014-9929-9) PMID: [24952166](https://pubmed.ncbi.nlm.nih.gov/24952166/)
51. McCullough PA, Barnard D, Clare R, Ellis SJ, Fleg JL, Fonarow GC, et al. Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function. *Clin Cardiol* 2013, 36:611–620. doi: [10.1002/clc.22181](https://doi.org/10.1002/clc.22181) PMID: [23929781](https://pubmed.ncbi.nlm.nih.gov/23929781/)
52. Chang JM, Chen SC, Huang JC, Su HM, Chen HC. Anemia and left ventricular hypertrophy with renal function decline and cardiovascular events in chronic kidney disease. *Am J Med Sci* 2014, 347:183–189. PMID: [23426086](https://pubmed.ncbi.nlm.nih.gov/23426086/)
53. Jones H, Talwar M, Nogueira JM, Ugarte R, Cangro C, Rasheed H, et al. Anemia after kidney transplantation; its prevalence, risk factors, and independent association with graft and patient survival: a time-varying analysis. *Transplantation* 2012, 93:923–928. PMID: [22377790](https://pubmed.ncbi.nlm.nih.gov/22377790/)
54. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review. *Trop Med Int Health* 2010, 15 Suppl 1:1–15. doi: [10.1111/j.1365-3156.2010.02508.x](https://doi.org/10.1111/j.1365-3156.2010.02508.x) PMID: [20586956](https://pubmed.ncbi.nlm.nih.gov/20586956/)
55. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. *PLoS Med* 2007, 4:e298. PMID: [17941716](https://pubmed.ncbi.nlm.nih.gov/17941716/)